Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 12, Issue 3, Pages 554-562Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-6143.2011.03976.x
Keywords
Belatacept; clinical trials; efficacy; endpoints; safety
Categories
Ask authors/readers for more resources
Elements of the Food and Drug Administration (FDA) review of the clinical data that supported the approval of the Biologics License Application (BLA) for belatacept for prophylaxis of organ rejection in adult patients receiving a kidney transplant are summarized. The article is not intended as a comprehensive summary of the entire belatacept data submission. Rather, the discussion is meant to illustrate aspects of the FDA's process for evaluating efficacy and safety, using belatacept as an example.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available